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Biotechnology Patent Law Developments in Great 
Britain and the United States: Analysis of a 
Hypothetical Patent Claim for a Synthesized Virus 
1. INTRODUCTION 
Gene splicing, I an emergent exploratory tool, enables scientists to catalogue 
the 100,000 genes found in a human celJ.2 By mapping genes on chromosomes, 
scientists may be able to compile the data necessary to attempt therapeutic cures 
of human genetic disorders.3 Gene splicing may also facilitate economically 
viable production ofinsulin,4 interferon5 and other human medications,6 as well 
I. Gene splicing, also known as genetic engineering or recombinant DNA, provides the basis for 
designing specialized bacteria or other organisms such as viruses, fungi or tissue culture cells which will 
produce useful gene products or have useful functions as mutant cells. Associated applications utilize 
cloned genes or gene fragments as diagnostics in medical genetics. Boyer, The Age of Molecular Biology, 7 
APLA Q. J. 185, 189 (1979). Genetic engineering technology makes it possible for a researcher to isolate 
a single gene from an organism's total DNA, to recombine it with a carrier molecule of DNA and to 
introduce the recombinant DNA into a bacterial cell. Anderson & Diaumakos, Genetic Engineering in 
Mammalian Cells, ScI. AM., July, 1981, at 121. Different kinds of cells make different proteins, as 
instructed by the DNA encoded in the genes of the cells. Developments in molecular biology enable 
scientists to alter the instructions in bacterial cells, thereby designing bacteria that can synthesize 
nonbacterial proteins. The bacteria are "recombinants." If the recombinant has an important biomedi-
cal application, "a culture of the recombinant bacteria, which can be grown easily and at a low cost, will 
serve as an efficient factory for producing" that recombinant. Gilbert & Villa-Kamaroff, Useful Proteins 
from Recombinant Bacteria, SCI. AM., Apr., 1980, at 74. Developments in genetic engineering techniques 
afford a researcher the means by which to "isolate one of the million-odd genes of an animal cell, to fuse 
that gene with part of a bacterial gene and to insert the combination into bacteria. As those bacteria 
multiply they make millions of copies of their own genes and of the animal gene inserted among !hem." 
Id. See also Sun, More Progress on Gene Transfer, 213 ScI. 996 (1981) [hereinafter cited as Sun]. For a 
discussion of recent developments involving biotechnology and animal genetics, see L. F. CAVALIERI, 
THE DOUBLE-EDGED HELIX (1981). 
2. Sun, supra note 1, at 997. If a gene of unknown function is inserted into bacteria, it can act as a 
probe that allows scientists to examine its effect. "Recombinant DNA research has revealed that genes 
are fungible; animal genes function perfectly well within bacteria and bacterial genes within animal 
cells, confirming the unity of nature." Singer, Recombinant DNA Revisited, 209 ScI. 1318 (1980). For an 
historical examination of the changing concept of the gene, see Chanibou, Split Genes, ScI. AM., May, 
1981, at 60 [hereinafter cited as Chanibou]. 
3. Chanibou, supra note 2, at 61. More than 2000 human diseases are caused by a single abnormality 
in any particular gene which embodies the genetic blueprint for making a single protein. Id. Even 
though the abnormality forms only a minute percentage of one gene among the many thousands 
needed to create a human being, that small abnormality can produce large-scale deleterious effects. 
Possible effects from such genetic abnormality include physical deformity, hormone problems, heart 
failure, poorly-clotting blood and mental retardation. Id. See also Marx, Genes That Control Develnpment, 
213 SCI. 1485 (1981) (describing the application of recombinant DN A techniques to the Mediterranean 
fruit fly in order to examine the genes that control development of higher organisms); and Inadmissible 
Evidence, ScI. AM., Dec., 1981, at 78 (describing advances in cancer research via genetic engineering 
methods). 
4. Insulin is the hormone that enables the body to burn sugar for energy. Of the 1.8 million diabetics 
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as improving agricultural output. Through gene splicing, scientists may be able 
to develop crops which provide their own fertilizer and which can grow in 
minerally deficient soils.7 Like most emergent technology, genetic engineering 
has scientific, economic and legal implications. 
Scientists began genetic engineering ("recombinant DNA") research at aca-
demic centers. University scientists traditionally engage in pure research, regard-
less of the prospects of commercial success.8 This research has now spread to the 
commercial world as well.9 As large corporations have recognized the potential 
for profit through genetic engineering,IO scientists have begun to serve as corpo-
in the United States using insulin, 5% suffer allergic reactions from the natural insulin extracted from 
animal pancreases. Chanibou, supra note 2, at 62. Insulin synthesized by recombinant DNA techniques 
results in an unlimited supply of non-allergic human insulin. See generally R. W. OLD & S. B. l'RIMROSE, 
PRINCIPLES OF GENETIC ENGINEERING: AN INTRODUCTION TO GENETIC ENGINEERING (1980); J. MORGAN 
& W. J. WHELAN, RECOMBINANT DNA AND GENETIC EXPERIMENTATION (1979); M. V. VOLKENSTEIN, 
MOLECULAR BIOPHYSICS (1977). 
5. Interferon, a protein regularly produced by the body, is a virus-fighting agent of unmatched 
strength but problematic power. M. EDELHART & J. UNDENMANN, INTERFERON: THE NEW HOPE FOR 
CANCER 17 (1981). Researchers have shown interferon to be potently effective against any virus. Id. 
Although there are currently eight persons in the world receiving treatment of genetically engineered 
interferon, scientists must better understand interferon's causes and effects before marketing it. 
Traditional methods of producing interferon are costly; one pound of the substance is worth $10 
billion.Id. Natural interferon treatment costs approximately $150 per day, but synthetic production 
could lower the price to $1 per day. Id. These financial considerations have not been overlooked by 
investors, who have financially spurred interferon research. Id. Interferon is currently being tested at 
the Medical Research Council's Common Cold Unit in Salisbury, England as a preventative of 
rhinovirus infection, one of the causes of the common cold. Walgate, Interferon Used At Last, 295 NATURE 
273 (1982). 
6. Additional medications which may be biotechnologically synthesized include human growth hor-
mone (used to treat dwarfism, and traditionally only available in limited quantities from pituitary glands 
of cadavers); urokinase (which dissolves blood clots); thymosin alpha-I (a hormone for treatment of 
brain and lung cancer); and beta-endorphin (the brain's painkiller). Chanibou, supra note 2, at 63. 
7. Demain & Solomon, Industrial Microbiology, SCI. AM., Sept., 1981, at 67. Recent advances in 
molecular biology have generated interest about the prospective application of novel microbiological 
techniques in a wide range of industrial roles. Genetically engineered soybean strains may boost by 10% 
the yield of U.S. soybean, a crop which is worth about $16 billion annually. Biotechnology Boom Reaches 
Agriculture, 213 SCI. 1339 (1981). Other biotechnological affects on the food chain involve soil im-
provement and task-specific enzymes.Id. See generally Blair, Test-Tube Gartkns, 3 SCI. 82, April, 1982, at 
70; Sci. AM., Sept., 1981 (special issue on industrial microbiology). 
8. Society looks to the technical community for warning, guidance and protection. Whether the 
needs be informational, such as effects of cykamates or DDT, or goal-oriented, such as the space 
exploration program, the public has given special status to highly-trained people like scientists. Society 
invests in the training and professional development of scientists, researchers and engineers by provid-
ing substantial public subsidy of academic and research facilities. The professions may choose the 
direction of research, enforce the quality of work and direct the allocation of public funds within their 
subject area. Concomitantly, society places certain trusts and responsibilities in the professions. The 
professions, in turn, are obliged to govern themselves and are committed to the service of society. 
W.LoWRANCE, OF ACCEPTABLE RISK: SciENCE AND THE DETERMINATION OF SAFETY 120-26 (1976). See abo 
Jasanoll & Nelkin, Science, Technology, and the Fruits of Jtulicial Competence. 214 Sci. 1211 (1981) (dis-
cussing the resolution of technological controversies in the judicial arena). 
9. The Business of Research, SCI. AM., Feb., 1982, at 70. The article describes the financial potential of 
genetic engineering, its consequent attraction to investors, and the financial relationships between 
corporations and educational institutions. 
10. Since 1978, at least 40 new bioengineering companies have been formed. Weber, A New Industry 
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rate advisors for companies engaging in such research. Many of these scientists 
are now involved in goal-oriented experimentation in conjunction with bioen-
gineering firms. I! 
Springs to Life. VENTURE, May, 1981, at 88. Commentators estimate that 70 to 100 new bioengineering 
companies are now in existence. Rosenberg, The Promise of Profits in Genetics, Boston Globe, Sept. 14, 
1981, at 1, col. 1. A representative of E. F. Hutton estimates that investment of private capital for 
genetic research will involve $1. 9 billion by 1985. Bus. WEEK, June 30, 1980, at 48, col. 2. One example 
of the financial significance of this investment is the case of Genentech, Inc. When the corporation 
entered the over-the-counter market with a $ 36 million stock offering in October, 1980, its opening 
price of $35 per share rose in minutes to $89. Many similar companies received such unprecedented 
initial responses. Some analysts predict, however, that those responses will not continue, for at least 
three reasons: Genentech stock was offered during a particularly bullish market; Genentech was the 
first biotechnology company to go public; and Genentech kept the number of issues relatively low at 1 
million shares. Sun, Genentech: Is Its Glamor Gone?, 211 SCI. 262 (1981). 
The collapse of another $40 million biotechnology venture has prompted its underwriter, E. F. 
Hutton, to offer biotechnology tax shelters. The original biotechnology venture, DNA Science, was to 
have branches in Israel, Ohio and California. The company also employed a Nobel prizewinner as a 
staff member. The original structure of DNA Science was similar to that of a holding company; small 
subsidiary companies established near major universities would conduct its business to accommodate 
specific research projects. The subsidiary companies would market the products resulting from the 
projects, and the researching scientist would maintain an equity interest in the venture. The capital 
acquisition plan unraveled when corporate investors (Allied Chemical and Johnson & Johnson) wanted 
proprietary rights to DNA Science's products. E. F. Hutton is now attempting to restructure an 
organization to take advantage of the newly enacted 25% tax credit for incremental investments in 
~esearch and development. If successful, the biotechnology tax shelters will resemble investments made 
in oil and gas drilling, movie productions, real estate and race horses. Norman, First Casualty in the 
Biotechnology Derily, 213 SCI. 1087-90 (1981). See al50 Wade, How to Keep Your Shirt -If You Put It in Genes, 
213 SCI. 26 (1981). 
11. See note 10supra; Sherman, MIT Weighs Biomedical Affiliate OK, Boston Globe, October I, 1981, at 
28, col. 1. 
Potential conflicts of interest arise when academicians engage in pure research and at the same time 
serve in an advisory capacity to commercial venture. Although some observers regard these relation-
ships as potentially problematic, most observers agree that society benefits from the commercial 
application of academic research. The Business of Research, SCI. AM., Feb., 1982, at 70 [hereinafter cited 
as The Business of Research]. Several concerns exist regarding an academic researcher serving in the 
management of a company whose business is closely related to his research, such as: the possibility that 
basic research will be subsumed by applied research offering financial profit, rather than fundamental 
insights; the likelihood that corporate secrecy will hamper the relatively free exchange of information in 
the academic community; and the chance that the nature of advanced teaching will focus students solely 
on financially rewarding subjects. Id. See Can Even Mere Knowledge Be A Threat7, 295 NATURE 269 (1982) 
(addressing the issues when conflict arises between academic freedom and national security). See also 
Making Private Interests Public, 295 ScI. 357 (1982) (describing new regulations proposed by California's 
Fair Political Practices Committee which would require scientists to report potential conflicts of interest). 
The practice of faculty members serving as consultants to industry is not without precedent. Gener-
ally, chemistry and engineering firms have adopted such relationships without adverse effects on 
research. For instance, developments in lasers and semi-conductors were marked by the combined 
efforts of businesses and universities. Not only do many of the high technology firms owe their vitality to 
the participation of university faculty, many universities have in the past utilized patents on innovations 
by their faculty as a source of revenue. The Business of Research, supra, at 70. For instance, Indiana 
University receives substantial income from its patent on the fluoride solution used in dentistry and the 
University of Florida profited from its patent on the beverage formula sold as Gatorade.Id. For a report 
on a patent dispute between two groups of researchers, see Wade, LaJolia Biologists Troubled ily the Midm 
Factor, 213 SCI. 623, 628 (1981) [hereinafter cited as Wade]. 
Universities with coherent patent and licensing strategies will not lose the benefits of research 
accomplished in their laboratories. For instance, Stanford University is expecting applications from 200 
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Patent law in Great Britain and the United States provides an officially 
sanctioned incentive system which encourages disclosure to the public of new 
and useful inventions.12 The patentee exchanges full and complete disclosure of 
how to make and use the claimed invention for the court-protected right to 
exclude others from making, using or selling the claimed invention for the 
statutory period. 13 A patentee would be reluctant to invest time and money in an 
invention without assurance of protection from easy and inexpensive duplication 
of his invention by others. The existence of a protective patent system has the 
effect of encouraging scientists to proceed with inventions for which they can 
claim exclusive rights. Thus, the effect of the patent system is to assure an open 
marketplace for technological ideas. 14 
By providing an incentive for developing and marketing such discoveries, the 
patent systems in Great Britain and the United States play an integral role in the 
development of biotechnology in their respective nations. 15 Analysis of recent 
legal developments affecting genetic engineering provides insight into what is, 
and what should be, the role of patent rights in developing and applying this 
technology. The British patent system is currently undergoing general revision 
due to the enactment of Patents Act 1977.16 In the United States, the pat-
entability of genetically engineered organisms was the focus of the Supreme 
Court in Diamond v. ChakrabartyY In Chakrabarty, the Supreme Court deter-
mined that the claimant's microorganism was patentable under the PatentAct of 
1952.18 
One aspect of biotechnology with which British and U,S. patent law has not yet 
addressed is the synthesis of a virus with which to infect a bacterium. Physiologi-
cally, a virus is radically different from a microorganism, and presents issues 
that distinguish its patentability from that of a microorganism.19 Since neither 
firms for the licensing of its patented gene splicing technology. Holden, Briefing, 213 ScI. 1089 (1981). 
The nonexclusive license is available to any commercial user of the process for an initial fee of $1 0,000 
plus an annual fee of $1 O,OOO./d, The royalty rate will be 1 % on net sales up to $5 million, and 0.5% on 
sales above $10 million annually. [d. Annual revenues could reach $1 million in four or five years. [d, 
Often decades pass before scientific discoveries leave the laboratory and find everyday application. 
"Vannevar Bush's quip that the difference between basic and applied sciences is 'about 20 years' may 
still be true in chemistry or engineering. With molecular biology, however, the gap often appears to 
have shrunk to a matter of weeks." Wade, supra, at 628. Beneficial research techniques spawned by 
recombinant DNA "were unimaginable even five years ago," states one observer, Maxine Singer of the 
National Cancer Institute. Singer, Recombinant DNA Revisited, 209 ScI. 1318 (1980). "And molecular 
biologists alone did not accomplish all this. They had unprecedented support from enlightened societies 
and governments. It has been a joint venture, and we should celebrate together." [d, 
12. Richey, Implications of the Plant Patent Act for the Patentability of Microorganisms, 39 MD. L. REv. 376, 
376 (1979) [hereinafter cited as Richey]. 
13, [d. 
14, [d. For the consumer, the system fosters an ever-widening choice of goods and services.!d. 
15. See notes 12-15 and accompanying text supra, 
16. Patents Act, 1977, ch. 37, §§ 1-4, 
17. 447 U.S, 303 (1980). 
18. !d. The Patent Act of 1952, 35 U.S,C. §§ 101-103 (1970). 
19. A microorganism is a living entity with a specific metabolism and capable of reproduction. A 
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Great Britain nor the United States has instituted a patent claim for a synthesized 
virus, this Comment anaiyzes the current trend of biotechnology patent law in 
Great Britain and the United States through the use of a hypothetical patent 
claim for such a virus. Specifically, the author examines the statutory provisions 
of patentability in Great Britain and in the United States, comparing the means 
by which the two patent systems have faced recent advances in biotechnology. 
The author presents the historical background presaging Great Britain's enact-
ment of the Patents Act 1977 and discusses the three conditions for patentability 
under the Patents Act 1977: novelty, inventive step and industrial application. 
The author then reviews the policies underlying U.S. patent law and the re-
quirements for patentability under the Patent Act of 1952 in light of the Chak-
rabarty decision. By examining the British and American patent systems in terms 
of a hypothetical claim for a synthesized virus, the author concludes that both 
patent systems broadly afford patentability for such emergent technology. 
II. BIOTECHNOLOGY PATENT LAW IN GREAT BRITAIN 
A. Background of the British Patent Law System 
Great Britain has long recognized the need for a patent system.20 However, 
rapid advances in technology during the last decade and the resulting accelera-
tion of scientific invention21 caused British laws relating to the protection of 
virus, however, is incapable of performing the normal functions of life (such as reproduction) unless it is 
sustained by a living, "host" cell. This total dependency of viruses is called obligatory parasitism. 
Furthermore, unlike organisms, viruses contain no cellular structure. These unique characteristics have 
caused many biologists to classify viruses as somewhere between the living and non-living. See generally 
J. D. EBERT, A. G. LoEWY, R. S. MILLER, H. A. SCHNEIDERMAN, BIOLOGY (1973) [hereinafter cited as 
EBERT]; M. J. PELCZAR, JR., R. D. REID, E. C. S. CHAN, MICROBIOLOGY (1977) [hereinafter cited as 
PELCZAR]. 
Viruses are chemically definable compositions, and can propagate only in certain living cells. One 
researcher described viruses as: 
the elegantly symmetrical particulate structures composed essentially of a molecule of nucleic 
acid encapsulated in a protein coat. They can exist outside the cell, but there they are inert. 
Once inserted into a cell, however, their nucleic acid (RNA or DNA) reprograms the cell's 
metabolic apparatus to the service of the virus; the nucleic acid replicates and is encapsulated, 
in the process destroying the cell and releasing a new crop of virus particles. 
Novick, Plasmids, 243 ScI. AM., Dec., 1980, at 102. A great deal of time and effort has been spent on 
research involving the relationship of viruses and cancer. Investigators are discovering that gene 
alterations contribute to the development of many cancers. Using gene transferring techniques, "re-
searchers are gaining the ability to isolate, clone and study in detail transforming genes from cancers 
that have arisen spontaneously or been induced by chemicals." Marx, Gene Transfer Yields Cancer Clues, 
215 SCI. 955, 955 (1982). 
20. McFarlane, A New Patent Lawfor the United Kingdom, Scots Law Times, Dec. 18, 1977, at 255-68, 
col. 2. [hereinafter cited as McFarlane]. 
21. [d. Great Britain has begun to establish science parks, which link businesses with universities, in 
much the same manner as found in similar establishments in the United States. Cross, Science in the Park, 
93 NEW SCIENTIST 432 (1982). These parks produced beneficial results for both business and academia; 
the university earned money and students were exposed to the business aspects of commercially 
developing their discoveries. [d. In both Great Britain and the United States, parks initially focused on 
industries such as computer manufacturers, software companies, electronics concerns and the research 
divisions of pharmaceutical firms. More recently, science parks have engaged in genetic engineering. [d. 
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industrial and intellectual property rights to become outdated. Existing law22 -
The Patents Act 1949 and The Copyright Act 1956 -lacked sufficient flexibility 
to deal with the new concepts for which inventors sought patent protection.23 
This inflexibility was apparent in cases of new technologies, such as software data 
processing, which had fundamentally altered previously existing processes.24 
The quarter century between Great Britain's last two patents acts was a period 
of great activity in the industrial property field, marked by a series of interna-
tional conventions and by new patent laws in many countries.25 Patent systems 
existing in Great Britain and elsewhere were unable to handle efficiently the 
worldwide technology explosion in which technological innovations were being 
applied to old handcraft industries.26 The advances in areas such as farming, 
home equipment and wholesale and retail trading became increasingly complex 
and transnational in character, as did developments in communications, com-
puters and other advanced technology. 
The scope of these technical innovations led to two types of problems for the 
existing patent systems. The first problem was that the number of applications 
and the complexity of potential patents increased to such an extent as to over-
burden the systemP The second problem which emerged in recent years was 
the insular nature of the patent systems. Each nation had developed its own 
patent laws with little regard to the corresponding laws of other nations. As a 
result, procedural and substantive law varied from one country to another.28 
The British government recently announced its decision to boost biotechnology research in the 
universities. Carlton, And British Universities Grasp the Biotechnology Nettle, 93 NEW SciENTIST 213 (1982). 
A scientist in the Department of Industry suggests coordinating research and development to make the 
most of scarce resources and to ensure that Great Britain does not fall behind in the biotechnology race. 
Biotechnology will be the subject of the next investigation of the House of Commons Select Committee 
for Education, Science and Arts, in order to consider government policy on biotechnology, research, 
development and application. [d. 
22. The Patents Act, 1949, 12, 13 & 14 Geo. 6, ch. 87; The Copyright Act, 1956,4& 5 Eliz. 2,ch. 47. 
23. McFarlane, supra note 20, at 265. The drafters of the original patent legislation did not foresee 
the extent to which innovation would outstrip traditional notions of invention and patent protection. Id. 
S.e also Gallagher-Daggitt,lnnovation in Perspective, 93 NEW SCIENTIST 9-19 (1982) [hereinafter cited as 
Gallagher-Daggitt] (presenting a series of articles describing Britain's general approach to industrial 
research and development). 
24. Gallagher-Daggitt, supra note 23, at 9-10. See also notes 138, 141 & 142 and accompanying text 
infra. 
25. Michaels, The British Patents Act of 1977, 13 INT'L LAw. 667, 669 (1979) [hereinafter cited as 
Michaels]. Nations which enacted new patent laws in the last 15 years include Denmark, Finland, 
France, Germany, Japan, the Netherlands, Norway, Sweden and Switzerland. [d. For a synopsis Qf these 
patent systems, see id. at 668-71. 
26. [d. at 668. 
27. [d. Because the examining patent offices could not keep pace with the volume and complexity of 
the applications filed, the patentees and industries were not aware of what they would be prohibited 
from patenting. [d. The British Patent Office was analyzed by a Parliamentary committee in 1970 as 
being "in arrears of some 47,000 unexamined specifications," which represented about one year's work. 
THE BANKS' COMMITTEE, THE BRITISH PATENT SYSTEM: REpORT OF THE COMMITTEE TO EXAMINE THE 
PATENT SYSTEM AND PATENT LAw, CMD. 4407, at 24-26, 95-99 (1970) [hereinafter cited as BANKS' 
COMMITTEE]. 
28. Michaels, supra note 25, at 668. The growth in transnational trade and exchange of technology 
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highlighted the differing patent systems. Applicants seeking patent protection in various nations faced 
different application procedures and standards. These separate patent systems entailed a great duplica-
tion of effort by the patentee and the examining patent office. Furthermore, the applicant faced 
different definitions of the invention and novelty requirements. [d. 
29. [d. For an overview of the various conventions, conferences and statutory amendments preceding 
1977, see id. at 668-71. 
30. BANKS' COMMITTEE, supra note 27, at 24-26. 
31. The Department of Trade, the department of state which controls the patent office, presented 
PATENT LAw REFORM, CMD. 6000, at I (1975) to Parliament. The report stated that: 
!d. 
!d. 
Modern industrial economies assume a high level of technology. A capacity to take advantage 
of technical innovation will continue to be an important factor influencing British industry's 
competitiveness in world markets. But innovation is frequently expensive and the commercial 
risks can be high. The protection given by the patent system provides a stimulus to invention 
and innovation, encouraging industry to strike out along new lines. Nonetheless, the system 
must evolve in response to changing conditions if it is to make its full contribution to the health 
of the British economy. 
32. [d. 
The government accepts most of the main recommendations of the Banks' Committee and 
intends to introduce legislation during the next Parliamentary Session revising the patent 
system: 
(i) so that it is in tune with modern trends and sufficiently flexible to accommodate future 
changes in technology; 
(ii) to streamline procedures for obtaining patents; 
(iii) to establish a Court specially equipped to hear patent cases; 
(iv) to take account of international developments in which successive British Governments 
have played a leading part in the interest of our industry and commerce. 
33. Cooper, The Patent System and the 'New BioloFrY,' 8 RUTGERS j. COMPUTERS, TECH. & L. I (1980) 
[hereinafter cited as Cooper]. Recent developments abroad reflect the tendency of other nations to 
promote technology through patenting systems. The German Patent System experienced expansive 
interpretation of its 1877 definition of patentable subject matter. The original definition was inter-
preted as a teaching of a technical character employing physical and chemical means of a predictable 
nature. This definition was unworkable for advances in science and technology. Ex parte Schreiner, I 
INT'L REv. INDUS. PRoP. & COPYRIGHT L., 136, 137 (1970) (Budesgerichtshof 1969) ("Rote Taube"/Red 
Dove), as cited in Cooper, supra, at 29, n. 148. 
The Japanese Patent office recently published "Guidelines Relating to Examination of Inventions of 
Microorganisms." English translation by A. Aoki & Associates, AIPPI j., Sept. 1979, at 151-55 as cited in 
Cooper; supra, at 31. Those guidelines indicate that country's intent to promote inventive technology. 
[d. For instance, "microorganisms" are defined to include "yeasts, molds mushrooms, bacteria, ac-
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Britain's exportation of emergent technology significantly affected its interna-
tional balance of payments.34 
The United Kingdom later ratified several international patent conventions in 
order to broaden the scope of its own patent system.35 One of the international 
conventions which Britain ratified was the Patent Co-operation Treaty.36 That 
treaty established an international patent system for the initial filing and cen-
tralized searching for patent applications.37 Great Britain also ratified the Euro-
pean Patent Convention (EPC),38 which defines a uniform European patent law 
and procedure. By submitting a single application to the European Patent 
Office, one obtains a European patent, which has the effect of a national patent 
in all of the contracting states.39 Thus, the successful patentee acquires a collec-
tion of national patents.40 
tinomycetes, algae, viruses, protozoa and the like, and for convenience, cultured tissues of animals and 
plants as well." Id. 
The French government has signaled its intention to sponsor special programs in biotechnology, 
micro-electronics, and new sources of energy. Walsh, French Government Bulletin on Science and Technol-
ogy, 213 ScI. 420 (1981). Under the Socialist regime of President Fran~ois Mitterand, the government 
intends to use research and development as a major tool for achieving economic recovery. !d. 
In a bid to keep up with developments abroad, India's Prime Minister, Indira Ghandi, recently 
announced that her government will establish a National Biotechnology Board to coordinate research in 
the field. Agarwal, India Sets Up Biotechnology Board, 93 NEW SCIENTIST 213 (1982). Government 
expenditures for biotechnology research will be approximately $15 million over the next three years. I d. 
Pakistan also recently established two centers to carry out research on genetic engineering. Frederick, 
Pakistan Joins Gene Club, 93 NEW SCIENTIST 488 (1982). 
The Netherlands government recently decided to allocate 4 million guilders ($1.25 million) a year to 
support biotechnology research. Becker, Going Dutch, 295 NATURE 91 (1982). 
The recent meeting of the Soviet Academy of Sciences stressed the biotechnology achievements in the 
U.S.S.R. Rich, Keefring a Secret, 295 NATURE 275 (1982). 
34. Cooper, supra note 33, at 36. 
35. CONVENTION OF THE GRANT OF EUROPEAN PATENTS (EUROPEAN PATENT CONVENTION), CMD. 5656 
(1974); PATENT CO-OPERATION TREATY, CMD. 4530 (1970); and the CONVENTION FOR THE EUROPEAN 
PATENT FOR THE COMMON MARKET (COMMUNITY PATENT CONVENTION), 0.]. EUR. COMM. (No. K. 17) 
(1976). 
36. PATENT CO-OPERATION TREATY, CMD. 4530 (1970). Signators to the treaty were: Algeria, Brazil, 
Canada, Denmark, Finland, Federal Republic of Germany, Holy See, Hungary, Republic of Ireland, 
Israel, Italy, Japan, Norway, Phillippines, Switzerland, United Arab Republic, United Kingdom, United 
States and Yugoslavia.ld. at 42. 
37. McFarlane, supra note 20, at 265. The draftt'f~ought uniformity of the patenting procedure.ld. 
38. CONVENTION OF THE GRANT OF EUROPEAN PATENTS (EUROPEAN PATENT CONVENTION), CMD. 5656 
(1974). 
39. Vittoria, The Patents Actl977, 41 MOD. L. REv. 329, 324 (1978) [hereinaft«r cited as Vittoria]. The 
European Patent Office in Munich carries out the examination for patentability. !d. 
40. Applicants have several objections to the application process, one of which was its relatively high 
cost (approximately $3500). Katona, Beating the High Cost of European Patents, 77 PAT. T.M. REv. 3 
(1979). There exists both procedural and legal drawbacks as well. Some Drawbacks to the European Patent, 
77 PAT. T.M. REv. 254 (1979). On a procedural level, the complexity and variations in terms present 
difficulties. Textual regulations are twenty to thirty times greater in length than regulations defining 
national systems. Third party opposition is more readily facilitated, and translation requirements 
further expand the chances of rejection on intricate procedural grounds. As a result, the duration of the 
European patent procedure is extremely protracted. !d. 
The prime legal drawback to the European patent is its fragility. A European patent will not be 
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Great Britain's Patents Act 1977 is a modernization of that country's patent 
system and embodies its ratification of the EPC.41 The Act repeals the entire 
Patents Act 1957,42 as well as certain provisions of the Patents Act 194943 and the 
Copyright Act 1956.44 The Act introduces several changes in the substantive law 
and procedure for obtaining patents.45 Although the new Act does not explicitly 
determine the patentability of a synthesized virus, a discernible policy appears to 
favor granting patent protection in such cases.46 
The Act introduces absolute standards of patentability which an applicant 
must satisfy before receiving a patentY The standards also continue to apply 
after the grant of a patent.48 In order to be patentable in Great Britain, an 
invention must be new, involve an inventive step, be capable of industrial appli-
stronger than a national patent. This is due first to the absence of title before issue of the patent and 
second to the more limited scope of the European patent due to its vulnerability to third party 
opposition. [d. For a history of the developing harmonization of the European patent system, see Beier. 
The European Patent System. 14 VAND. J. TRANS. L. I (1981). 
41. Part II (§§ 77-95) of the Patents Act 1977 provides for the assimilation of a European patent into 
the British system. such that a successful application made under either the Patent Co-operation Treaty 
or the EPC will become effective patents in the United Kingdom. 
42. The Patents Act. 1957.5 & 6 Eliz. 2. ch. 13. 
43. The Patents Act. 1949. 12. 13 & 14 Geo. 6. ch. 87. 
44. The Copyright Act. 1956. 4 & 5 Eliz. 2. ch. 47. 
45. Some of the direct effects of the Patents Act 1977 are that: the term of the patent is extended 
from sixteen to twenty years (§ 25); third party attacks are confined to granted patents (§§ 72-74); a 
statutory basis is established for deciding whether an invention made by an employee belongs to that 
employee. or alternatively to his employer (§§ 39-43); secret use of an invention is no longer a ground 
for invalidating a subsequent patent for the same invention (§§ 86-88); the Patents Appeal Tribunal is 
replaced by a Patents Court which is part of the Chancery Division (§§ 96-108); and the overall Patent 
Office procedure is streamlined by early search and early publication provisions (§§ 17-21). thereby 
preventing the lengthy opposition proceedings possible under the Patents Act 1949. 
46. The British Department of Trade sanctioned the policy of spurring investment in technology by 
way of patent protection. PATENT LAw REFORM. CMD. 6000 (1975). See note 31 supra. 
47. Patents Act. 1977. ch. 37. § I. 
1. Patentable inventions 
(I) A patent may be granted only for an invention in respect of which the following 
conditions are satisfied. that is to say -
(a) the invention is new; 
[d. 
(b) it involves an inventive step; 
(c) it is capabk of industrial application; 
(d) the grant of a patent for it is not excluded by subsections (2) and (3) below; 
and references in this Act to a patentable invention shall be construed accordingly. 
(2) It is hereby declared that the following (among other things) are not inventions for the 
purposes of this Act. that is to say. anything which consists of -
(a) a discovery. scientific theory or mathematical method; 
(b) a literary. dramatic. musical or artistic work or any other aesthetic creation whatsoever; 
(c) a scheme. rule or method for performing a mental act. playing a game or doing business. 
or a program for a computer; 
(d) the presentation of information; 
but the foregoing provision shall prevent anything from being treated as an invention for the 
purposes of this Act only to the extent that a patent or application for a patent relates to that 
thing as such .... 
48. H. BRETf. THE PATENTS ACT, 1977.6-7 (1977) [hereinafter cited as BRETf]; McFarlane. supra 
note 20. at 266. 
572 BOSTON COLLEGE INTERNATIONAL & COMPARATIVE LAW REVIEW [Vol. VI, No.2 
cation and not excludable from patentability by the statute.49 The statute ex-
pressly excludes from patentability discoveries, scientific theories and mathemat-
ical methods.50 These exclusions form a non-exhaustive list and closely follow 
prior law.51 
The new definition of patentability in the Patents Act 1977 conforms to that of 
the EPC Articles 52 and 5.3. In order to ensure conformity with the EPC, the Act 
declares that the definition of patentability was designed to have, as nearly as 
practicable, the same effects as the corresponding provisions of the EPC.52 The 
Act requires that the British Patent Office and British courts take judicial notice 
of the EPC, the Patent Co-operation Treaty and the Community Patent Conven-
tion, as well as decisions and opinions of convention courts.53 Because of the 
harmonization sought between the British and international conventions,54 the 
EPC Guidelines55 will be discussed in interpreting British Patent Law. The 
Guidelines give general instructions as to the practice and procedure of the 
European Patent Office, and therefore are relevant when examining the Patents 
Act 1977. 
B. Conditions for Patentability in Great Britain 
Although there is no complete definition of "invention" III the Patents Act 
1977, the meaning of the word is fundamental to the operation of the Act. 56 The 
Patents Act 1949 defined "invention" as any manner of new manufacture.57 One 
group of commentators noted that that definition was in effect a definition of 
patentable subject matter.58 That group also indicated that the definition of 
invention in the Patents Act 1977 appears to encompass anything devised by the 
inventor.59 Nevertheless, the Act limits the grant of a statutory monopoly to 
49. Patents Act, 1977, ch. 37, § 1(1). 
50. Patent law theory has long held that discoveries of natural phenomenon are not patentable. 
P. ROSENBERG, PATENT LAw FUNDAMENTALS 13 (1979) [hereinafter cited as ROSENBERG]. 
51. Vittoria, supra note 39, at 326. 
52. Patents Act, 1977, ch. 37, § 130(7). 
53. Patents Act, 1977, ch. 37, § 91. 
54. CHARTERED INSTITUTE OF PATENT AGENTS, C.I.P.A. GUIDE TO THE PATENTS ACT 1977, at 7 (1980) 
[hereinafter cited as C.I.P.A. 1977]. 
55. EUROPEAN PATENT OFFICE, GUIDELINES FOR EXAMINATION IN THE EUROPEAN PATENT OFFICE 
(1979) [hereinafter cited as GUIDELINES]. The Guidelines were adopted in accordance with the EPC, art. 
10. They are intended to cover the normal proceedings of the European Patent Office. Although the 
staff of the European Pate!'t Office may depart from the Guidelines in exceptional cases, patent 
practitioners can expect the Office to act generally in accordance with the Guidelines. [d. at I. The 
Guidelines do not have the binding authority of a legal text. [d. 
56. C.I.P.A. 1977, supra note 54, at 7-8. 
57. Patents Act, 1949, 12, 13 & 14 Geo. 6, ch. 87, § 101. 
58. C.I.P.A. 1977, supra note 54, at 8. Prior to enactment of the Patents Act 1977, the Patent Office 
had a limited responsibility to ensure that patent applications fell within the concept of manner of new 
manufacture. No general standard of patentability existed, and the requirements for patentability were 
stricter only if the grant of a patent were opposed or its validity questioned in revocation proceedings. 
BRETT, supra note 48, at 6. 
59. C.I.P.A. 1977, supra note 54, at 8. 
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patentable inventions in terms of novelty, inventive step and capability of indus-
trial application. Section 1(5)60 of the Act incorporates flexibility by allowing the 
Secretary of State for Trade to vary the list of exclusions in order to ensure that 
the patent system responds to the developments of science and technology.61 
The three basic statutory conditions for patentability under the Patents Act 
1977 are novelty, an inventive step and capability of industrial application.62 An 
analysis of these three conditions indicates that the synthesized virus claim would 
meet these requirements. 
1. Novelty 
Novelty, as described under the Patents Act 1977,63 is a function of "the state 
of the art," requiring the inventor to assert his originality against the "public 
60. Patents Act, 1977, ch. 37, § 1(5). 
61. /d. The Act states: "The subsection (2) above for the purpose of maintaining them in conformity 
with developments in science and technology; and no such order shall be made unless a draft of the 
order has been laid before, and approved by resolution of, each House of Parliament." Id. 
62. /d. at § 1(I)(a)-(c). 
63. Id. at § 2. 
2. Novelty 
(I) An invention shall be taken to be new if it does not form part of the state of the art. 
(2) The state of the art in the case of an invention shall be taken to comprise all matter 
(whether a product, a process, information about either, or anything else) which has at any 
time before the priority date of that invention been made available to the public (whether in 
the United Kingdom or elsewhere) by written or oral description, by use or in any other way. 
(3) The state of the art in the case of an invention to which an application for a patent or a 
patent relates shall be taken also to comprise matter contained in an application for another 
patent which was published on or after the priority date of that invention, if the following 
conditions are satisfied, that is to say -
(a) that matter was contained in the application for that other patent both as filed and as 
published; and 
(b) the priority date of that matter is earlier than that of the invention. 
(4) For the purposes of this section the disclosure of matter constituting an invention shall 
be disregarded in the case of a patent or an application for a patent if occurring later than the 
beginning of the period of six months immediately preceding the date of filing the application 
for the patent and either -
(a) the disclosure was due to, or made in consequence of, the matter having been obtained 
unlawfully or in breach of confidence by any person -
(i) from the inventor or from any other person to whom the matter was made available 
in confidence by the inventor or who obtained it from the inventor because he or the 
inventor believed that he was entitled to obtain it; or 
(ii) from any other person to whom the matter was made available in confidence by any 
person mentioned in sub-paragraph (i) above or in this sub-paragraph or who 
obtained it from any person so mentioned because he or the person from whom he 
obtained it believed that he was entitled to obtain it; 
(b) the disclosure was made in breach of confidence by any person who obtained the matter 
in confidence from the inventor or from any other person to whom it was made 
available, or who obtained it, from the inventor; or 
(c) the disclosure was due to, or made in consequence of the inventor displaying the 
invention at an international exhibition and the applicant states, on filing the applica-
tion, that the invention has been so displayed and also, within the prescribed period, files 
written evidence in support of the statement complying with any prescribed conditions. 
(5) In this section references to the inventor include references to any proprietor of the 
invention for the time being. 
(6) In the case of an invention consisting of a substance or composition for use in a method 
of treatment of the human or animal body by surgery or therapy or of diagnosis practised on 
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knowledge" of the world, without any restriction as to time or geography.64 The 
Banks' Committee recommended such a novelty search, indicating that the 
closer the Patent Office's search approaches the whole field of the state of the art, 
the greater the presumption of the validity of the patent. 65 The standard of 
novelty under the Patents Act 1949 was the same as the test for infringement; a 
prior use in the United Kingdom would invalidate a claim.66 
The Patents Act 1977 definition of novelty is based on EPC Articles 54, 55 and 
89. Reference to the EPC Guidelines for Patent Offices provides insight as to the 
Act's novelty standard. The Guidelines indicate that a claim must be of a techni-
cal character. Specifically, the invention must relate to a technical field, involve a 
technical problem, and have definable technical features. 67 Such a definition 
accurately describes a synthesized virus because the virus' predictable features 
afford the scientist a solution to the problem of isolating research variables. 
Furthermore, the Guidelines explain that if the patentee can properly charac-
terize the product without reference to the development process and if the 
!d. 
the human or animal body, the fact that the substance or composition forms part of the state of 
the art shall not prevent the invention from being taken to be new if the use of the substance or 
composition in any such method does not form part of the state of the art. 
64. BRETT, supra note 48, at 8. The EPC, art. 54 and the Patent Co-operation Treaty, rule 31.1(a), 
both adopt a standard of absolute novelty. If the invention has been published or used anywhere in the 
world before the filing of an application, patenting of the invention is absolutely barred. The problem 
of concurrent applications is addressed in the Patents Act, 1977, ch. 37 § 2(3), which replaces the 
concept of "prior claiming" with the "whole contents" approach. Simply stated, the earlier of two similar 
patent applications will be deemed published for purposes of state of the art analysis. 
Section 2( 4) of the Act establishes the means by which non-prejudicial disclosures may be made by the 
patentee prior to filing. Because state of the art is construed broadly by the Patent Office, the patentee 
who provides information concerning his invention prior to filing should s,ecure confidentiality in order 
to ensure novelty at the time of filing. For further discussion of what constitutes existence within the 
state of the art, i.e., prior publication and earlier applications, see GUIDELINES, supra note 55, at 257-64. 
For further discussion concerning the extent to which patent examiners would search the prior art, see 
id. at 126-31. 
65. THE BRITISH PATENT SYSTEM: REpORT OF THE COMMITTEE TO EXAMINE THE PATENT SYSTEM AND 
PATENT LAw, CMD. 4407, at 69. 
66. The Patents Act, 1949, 12, 13 & 14 Geo. 6, ch. 87, §§ 32,50. In The British Thomson-Houston v. 
Metropolitan-Vickers (1928) R.P.C. I, 22, the Royal Patent Court stated that to deprive the claim of 
novelty, a prior use must have dealt with the same problem and achieved the same result. 
67. GUIDELINES, supra note 55, at 247. 
Section 1(3)(b) of the Patents Act 1977 excludes from patentability any variety of animal or plant or 
any essentially biological process for their production, not being a microbiological process or the product 
of such a process. The Chartered Institute of Patent Agents has indicated that the term plant or animal 
varieties might include some microorganisms; "hence the position as to claims to microorganisms per se 
is not clear, but microorganisms (as well as inanimate products) when produced by a microbiological 
process can be patented." C.LP.A. 1977, supra note 54, at 11. The Institute further notes that the term 
microbiological process may be defined by the extent to which technical intervention by man exists in 
the process.ld. There is a positive correlation between the extent of technical intervention by man in the 
essentially biological process and the likelihood of patentability. Such a relationship is consistent with 
the underlying policy of a patent system to afford protection for man-made inventions. 
The synthesized virus is a product of a microbiological process, but that process is one with significant 
technical intervention by man. Thus, the Patent Office should not exclude the synthesized claim from 
patentability. 
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product is new in the absolute sense of having no previously recognized exis-
tence, then the product may be patentable per se.68 Hence, the claimant may be 
afforded an independent means by which to patent a synthesized virus. 
like discoveries, neither scientific theories nor mathematical methods are 
novel or patentable. 69 However, scientists who genetically manipulate a virus, so 
as to permanently alter its utility, produce a unique and novel product. 70 Such a 
product represents more than a mere theory or method. Therefore, the first of 
the three conditions for patentability is satisfied by the hypothetical virus claim. 
Even in the event that the British Patent Office determines the virus to be an 
already existing form,71 as an alternative one may obtain a patent for the new 
medical use of the known compound.72 Under the Patents Act 1949,73 an 
applicant was unable to obtain patent protection for known substances which 
had unexplained medical properties. 74 Because the substance was not novel, the 
patentees could not claim it was patentable per se.75 Furthermore, processes for 
the medical treatment of human beings have never been patentable. 76 However, 
under the 1977 Act, an applicant now can obtain a patent for new medical 
properties of known substances which the patentee reveals for the first time. 77 
The Act's provision corresponds to Article 54 of the EPe, and affords protection 
to the first applicant of a known substance or composition for human treatment, 
therapy, surgery or diagnosis. 
Although the use of a synthesized virus could conceivably involve human 
6B. GUIDELINES, supra note 55. at 249. 
69. [d. An invention which utilizes such theories, however, is not necessarily non-patentable. This 
approach applies to programs for computers and presentations of information. 
70. See notes 1-4 supra. 
71. See notes 63-64 and accompanying text supra. An already existing form would be within the state 
of the art, and consequently excluded from statutory protection. GUIDELINES, supra note 55, at 247. 
72. Patents Act, 1977, ch. 37, § 2(6). 
73. The Patents Act, 1949, 12, 13 & 14 Geo. 6, ch. B7. 
74. The Upjohn (Robert's) Application, (1977) R.P.C. 94, as cited in Vittoria, supra note 39, at 326 
n.1B. The applicant'S specification included claims to a method of reducing gastric secretion in mam-
mals by the systematic administration of certain compounds. The Patents Appeal Tribunal ruled that, 
under The Patents Act, 1949, a method of treatment of a human ailment with a known substance is not 
an invention. 
75. [d. at 326 n.1B. 
76. [d. 
77. PatenlS Act, 1977, ch. 37, § 2(6). Thus, under the old law, if the use oftrundleamine, known for 
the treatment of diabetes, was discovered, a later discovery that it is an effective anti-malarial agent 
could not be patented. Organon's Application, (1970) R.P.C. 574, as cited in Vittoria, supra note 39, at 
326, n.1B. The patent court, inShering A.G.'s Application, referred to the problem of the patentability of 
previously unexplained medical properties in dicta: 
It is no doubt sensible that a person who is able to produce a substance which, for example, 
would cure or prevent cancer, should, subject to safeguards, be offered a limited monopoly as 
a reward and the possibility of such a monopoly protection has undoubtedly resulted in 
enormous investment in research in the medical field. If this position is accepted, it is a little 
difficult to see why someone who by research effort devises a new method of using a known 
substance to achieve equally beneficial results should be denied patent protection. 
Schering A.G.'s Application, (1971) R.P.C. 337, 341, as cited in Vittoria, supra note 39, at 326, n.1B. 
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treatment, the virus claim probably would not fall within Section 2(6), which 
relates only to known substances or compositions. However, because a syn-
thesized virus is a substance of previously unknown and unique composition, the 
virus claim should meet the initial patentability requirement of novelty. 
2. Inventive Step 
The second condition for patentability under the Patents Act 1977 is that the 
virus must involve an inventive step.78 Inventive step and novelty are different 
criteria; novelty is a condition precedent to analysis for inventive step.79 An 
invention may be new, yet be so obvious as to lack an inventive step.80 Unless the 
invention is sufficiently original so as to contribute toward existing knowledge, it 
will not involve an inventive step sufficient to justify the grant of a patent.81 The 
term "obvious," as used in the Act, means that which does not go beyond the 
normal progress of technology, but which merely follows plainly or logically by a 
person skilled in the art.82 The Guidelines follow existing law and describe a 
"person skilled in the art" as one with the means and ability of an ordinary 
practitioner aware of the common general knowledge in the art. Nonetheless, 
the Guidelines stipulate that such a person is deemed to have "no imagination."83 
According to this standard, patent authorities probably would not consider a 
synthesized virus to be "obvious." The recombinant nature of the synthesized 
virus goes beyond the normal progress of technology, and involves sufficient 
exercise of skill and creativity to carry it beyond the realm of the obvious.84 
In conjunction with its analysis of obviousness, one !~roup of commentators 
notes that an inventive step may arise by devising a solution to a known problem 
or it may arise by arriving at an insight into the cause of a known phenomenon.85 
78. Patents Act, 1977, ch. 37, § 3. "An invention shall be taken to involve an inventive step if it is not 
obvious to a person skilled in the art, having regard to any matter which forms part of the state of the art 
by virtue only of section 2(2) above (and disregarding section 2(3) above)." Id. This section corresponds 
to EPC, art. 56. 
79. GUIDELINES, supra note 55, at 264. 
80.Id. 
8!. /d. Prior to the Patents Act, 1977, the Patent Office was required by law only to consider the 
novelty of patent applications, without regard to the existence of inventive step. Only if another 
patentee challenged the application was the applicant required to prove the existence of an inventive 
step. /d. 
82. C.l.P.A. 1977, supra note 54, at 17. Inventive step analysis has received criticism. See Pagenberg, 
The Evaluation of 'Inventive Step' in the European Patent System - More Objective Standards Needed, 9INT'L 
REv. INDUSTRIAL PROPERTY COPYRIGHT L. I, 121 (1978). 
83. GUIDELINES, supra note 55, at 267. 
84. See generally notes 1-3 supra, describing the techniques used by researchers utilizing genetic 
engineering techniques. 
85. C.l.P.A. 1977, supra note 54, at 17. The framers of the Guidelines stated that it is persuasive 
evidence of sufficient inventive step if the invention is of considerable technical value or provides a new 
technical advantage in fulfilling a "long felt want." GUIDELINES, supra note 55, at 275. Similar interpreta-
tion of the requirement was carried out by the Patent Office under the Patents Act 1949. See, e.g., 
Hickton's Patent Syndicate v. Patents and Machine Improvements Co., Ltd., 26 R.P.C. 339, 347 (1909). 
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the synthesized virus meets both of these criteria. The virus may afford a 
solution to a research problem because it is a non-random variable.86 For exam-
ple, in disease research, a scientist could synthesize a virus in order to effectuate 
a known result, thereby providing the experimenter with insight into the cause 
of the disease. Once the Patent Office finds that an inventive step exists, it will 
determine the proposed patent's capability of industrial application. 
3. Industrial Application 
In addition to being novel and involving an inventive step, the virus also must 
be capable of industrial application to qualify for a patent under current British 
law.87 An invention is capable of industrial application "if it can be made or used 
in any kind of industry, including agriculture."88 The courts have broadly 
interpreted what activities constitute "industry."89 The Patents Act 1977 does not 
require that the invention specifically be made or used in industry; the fact that 
the invention is capable of being used in industry is sufficient.90 
One problem of industrial application which might confront the virus claim 
86. See generally note 2 supra. A non-random variable is also referred to as a constant. Scientific 
research is optimally based on the control of all relevant factors (or constants), except one. The greatest 
difficulty in disease research is isolating and then controlling variables in an effort to determine the 
actual cause and effect relationship under investigation. A genetically manipulated virus facilitates the 
establishment of a constant; previously, such a control was unavailable. 
Gene splicing will enable researchers to acclerate the formidable task of identifying, locating and 
analyzing everyone of the more than 100,000 genes found in a human cell. See notes 2-4 and 
accompanying text supra; and Golden, Shaping Life in the Lab, Time, March 9, 1981, at 50-59 (asserting 
that history will view technology in terms of decades: 1940's - plastics; 1950's - transistors; 1960's-
computers; 1970's - microcomputers; and 1980's - genetic engineering). 
[d. 
87. Patents Act, 1977, ch. 37, § 4. 
4. Industrial application 
(1) Subject to subsection (2) below, an invention shall be taken to be capable of industrial 
application if it can be made or used in any ki~d of industry, including agriculture. 
(2) An invention of a method of treatment of the human or animal body by surgery or 
therapy or of diagnosis practised on the human or animal body shall not be taken to be capable 
of industrial application. 
(3) Subsection (2) above shall not prevent a product consisting of a substance or composition 
being treated as capable of industrial application merely because it is invented for use iri any 
such method. 
88. [d. at § 4( 1). One of the differences between the Patents Act 1977 and the EPC concerns the 
specific wording relating to "industrial application." The Act requires an invention to be "capable" of 
industrial application, whereas EPC Article 52 requires an invention to be "susceptible" to industrial 
application. The framers of the Guidelines regard these terms as synonymous. GUIDELINES, supra note 
55, at 9. 
The interpretation given under the Patents Act, 1949 to the expression "manner of new manufac-
ture" corresponds largely to the term "industrial application," according to one group of commentators. 
C.I.P.A. 1977, supra note 54, at 21. See also National Research Development Corporation's Application, 
(1961) R.P.C. 135. 
89. C.I.P.A. 1977, supra note 54, at 20; GUIDELINES, supra note 55, at 255. 
90. [d. The Guidelines note that very few inventions are excluded from patentability for lack of 
susceptibility of industrial application which are not already excluded by the statutory list relating to 
discoverid and the like. GUIDELINES, supra note 55, at 255. 
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arises in its use as a medical treatment. The Patents Act 1977 continues to 
exclude from patentability methods of treatment for humans and animals.91 
However, the Act does extend patentability to an invention relating to the "new 
medical use of a known substance."92 Thus, the discovery of medical properties 
of a known substance which had not been previously recognized may now be 
patented.93 
However, the patentability of the synthesized virus should not have to depend 
upon this expanded statutory limitation. As discussed earlier, the synthesized 
virus has its greatest utility in industrial application as a non-random variable in 
disease research.94 This potential application of the synthesized virus should 
qualify it as "industrially applicable," as contemplated by the framers of the Act. 
Assuming the virus meets the previous requirements of novelty and inventive 
step, it will be patentable under Great Britain's Patents Act 1977. 
III. BIOTECHNOLOGY PATENT LAW IN THE UNITED STATES 
A. Background of the U.S. Patent Law System 
U.S. federal patent law provides a constitutionally sanctioned95 incentive sys-
tem whereby the public marketplace determines any award for the inventor.96 
The patentee exchanges full and complete disclosure of how to make and use the 
claimed invention for the court-protected right to prevent others from the 
unlicensed production, use or sale of the particular invention or process for 
seventeen years.97 This right even extends against those who discover the inven-
tion or process through independent research.98 The award of patent protection 
91. See notes 72- 77 and accompanying text supra. 
92. Patents Act, 1977, ch. § 2(6). 
93. /d. 
94. See note 86 and accompanying text supra. 
95. U.S. CONST. art. I, § 8, cl. 8 authorizes Congress "to promote the progress of Science and useful 
Arts by securing for Limited Times to Authors and Inventors the exclusive Right to respective writings 
and Discoveries." 
96. See presentation by Chief Judge Markey at the Federal Judicial Center Workshop for District 
Judges, 80 F.R.D. 203, 205 (1979). Chief Judge Markey has said that "the patent system was the first 
freedom of information act" and the first "sunshine law." [d. The system is not based on profit. A patent 
on the unwanted is worthless in the marketplace. [d. 
97. 35 U.S.C. § 154 (1970). Richey, supra note 12, at 376. An inventor in the United States does not 
have a common law right to a monopoly on his invention. Holstensson v. V-M Corp., 325 F.2d 109, 125 
(6th Cir. 1963). An applicant must comply with congressionally established requirements as a condition 
to exercising such monopoly. [d. 
Once the applicant complies with these requirements and is awarded a patent, "there are established 
limits which the patentee must not exceed in employing the leverage of his patent to control or limit the 
operations of the licensee." Zenith Radio Corp. v. Hazeltine Research, Inc., 395 U.S. 100, 136 (1969). 
Such restrictions preclude the establishment of trade constraints and the acquisition of unreasonable 
royalty rates. Brulotte v. Thys Col., 379 U.S. 29 (1964). 
98. See Cataphote Corp. v. Hudson, 422 F.2d 1290 (5th Cir. 1970). Cataphote involved an alleged 
infringement of a trade secret regarding a gas-fired furnace for producing microscopic glass beads. The 
court noted that a patent is totally exclusionary for the period granted, whereas the trade is protected 
only so long as competitors fail to duplicate it by legitimate, independent research. [d. at 1295. 
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dispels the fear of easy and inexpensive duplication of a patentee's invention by 
others99 and encourages the patentee to publicize his invention. loo Full disclo-
sure in turn encourages innovation. lol By awarding protection in the form of a 
patent, the statute increases the sum of useful knowledge available to the pub-
lic. l02 
The primary purpose of the U.S. patent system is not to reward the patentee, 
but to advance the arts and sciences. loa The Supreme Court has found a strong 
manifestation of congressional intentl04 to promote technology and the useful 
arts. 105 The Court has therefore construed the patent statutes liberally so as not 
to preclude the development of new and emergent technologies. lOS Such an 
approach enhances the probabilty of success for a synthesized virus claim under 
U.S. patent law. 
B. Requirements for Patentability in the United States 
The Patent Act of 1952107 establishes the requirements one must satisfy in 
order to obtain a patent. Section 101 of the Act protects the invention or 
discovery of any new and useful process, machine or componsition of matter, or 
any new and useful improvement thereof.108 Like Great Britain,109 the United 
99. See Mandich, Venetian Patents, 30 J. PAT. OFF. SOC'y 166 (1978),as cited in Cooper, supra note 33, at 
37. 
100. Richey, supra note 12, at 376. See also Aronson v. Quick Point Pencil Co., 440 U.S. 257 (1979). 
"The patent system is beneficial as it encourages and rewards inventions, stimulates new ideas and 
enables the public to use the invention after the patent expires. Further, ideas in general circulation 
remain available for unencumbered public use." !d. 
101. Rosenberg, supra note 50, at 78. 
102. Great Atlantic & Pacific Tea Co. v. Supermarket Equipment Corp., 340 U.S. 147, 153 (1951). 
The case concerns the patentability of a combination patent claim for a grocer's cashier counter. The 
Court held that such a uniting of elements performs no additional or different function and is, 
therefore. an invalid patent claim.ld. at 152. See also text accompanying notes 12-15 supra. 
103. Richey. supra note 12. at 376. 
104. See Patent Law Codification and Revision: Hearings on H.R. 3760 Before Subcomm. No.3 of the House 
Comm. on the Judiciary, 82d Cong .• 1st Sess .• 20 (1951) (statement of Charles J. Zinn, Law Revision 
Counsel, Comm. on the Judiciary). The last general revision of the patent laws was the Act of July 8, 
1870.Id. See generally S. REp. No. 1979, 82d Cong., 2d Sess. 5 (1952); H. R. REp No. 1923, 82d Cong., 2d 
Sess. 6 (1952). 
105. Graham v. John Deere Co .• 383 U.S. I, 6 (1966). "It is the duty of the Commission of Patents 
and of the courts in the administration of the patent system to give effect to the constitutional standard 
by appropriate application. in each case, of the statutory scheme of Congress." Id. See also Diamond v. 
Chakrabarty, 447 U.S. 303 (1980). "In choosing such expansive terms as 'manufacture,' and 'composi-
tion of matter,' modified by the comprehensive 'any,' Congress plainly contemplated that the patent 
laws would be given wide scope. The relevant legislative history also supports a broad construction." Id. 
at 308, citing S. REp. No. 1979, 82d Cong., 2d Sess. 5 (1952); H.R. REp. No. 1923. 82d Cong., 2d Sess. 6 
(1952). 
106. See, e.g., Diamond v. Chakrabarty, 447 U.S. 303 (1980). 
107. The Patent Act of 1952, 35 U.S.C. §§ 101-103 (1970). 
108. 35 U.S.C. § 101 (1970). "[Wlhoever invents or discovers any new or useful process, machine, 
manufacture, or composition of matter, or any new and useful improvement thereof. may obtain a 
patent therefore .... " Id. 
109. See note 69 and accompanying text supra. 
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States issues a patent for the application of a principle, but not for the principle 
itself. 11 0 "Composition of matter" and "process" are the two methods of pat-
entability which are relevant to the synthesized virus claimYl 
1. The Synthesized Virus as a Composition of Matter. 
In patent law, composition of matter includes chemical compounds and physi-
cal mixturesY2 Just as a machine is a combination of parts, a composition of 
matter is a combination, union or association of ingredientsY3 Whether a 
machine is patentable may depend not only on the novelty of its components, but 
on the manner of their combination.114 Similarly, the patentability of a composi-
tion of matter may turn not only on the novelty of its ingredients, but on the 
manner in which these ingredients are combined.lls This combination must 
produce a unitary result. 116 Furthermore, the resulting product must exhibit a 
set of properties distinct from those possessed by its separate components.ll 7 
In light of these criteria, the Supreme Court, in Diamond v. Chakrabarty,118 
ruled upon the patentability of a man-made microorganism as a composition of 
matter. This case raised two issues. The primary issue involved the patentability 
1l0. Tilgham v. Proctor, 102 U.S. 707 (1880). The issuance of patent for the principle itself would 
have the effect of banning all further uses of the scientific principle. The unpatentability of products of 
nature is a distinction created by the British Parliament and implicitly retained in current patent law. 
Statute 21 James I, ch. 3 (1623). 
Ill. A third method of analysis, manufacture, is not as relevant as the composition of matter or 
process analyses are to the synthesized virus claim. The term "manufacture" is actually shorthand for 
article of manufacture and is derived from the English Statute of Monopolies, which speaks of "any 
manner of new manufactures." The Statute of Monopolies, 1623, 21 Jac. I, ch. 3. U.S. law has given a 
more restrictive construction to the term manufacture as a term of art than has British law, and excludes 
that which is within the ambit of other statutory classes of inventive subject matter. For instance, a court 
has held that the manufacture of a new product does not depend upon novelty of the process, but may 
result from an appropriate (and new) selection of the composite ingredients. General-Tire and Rubber 
Company v. Watson, 184 F. Supp. 344, 351 (D. D.C. 1960). Excluded from the term manufacture are 
articles whose appearance, properties, function, form, shape or size has been only negligibly altered by a 
manufacturing process whereby the essential character of the article remains a product of nature. 
RoSENBERG, sufrra note 50, at 78. 
112. RoSENBERG, sufrra note 50, at 78. 
113. Id. A chemical element is a combination of subatomic particles such as protons, electrons and 
neutrons. 
114. [d. A novel combination of elements which cooperate with each other so as to produce a new and 
useful result is patentable. Dal-Bac (Pty.), Ltd. v. Firma Astorwerk Otto Berning & Co., 244 F. Supp. 
516, 523 (S.D. N.Y. 1965). 
115. ROSENBERG, sufrra note 50, at 78. 
116. Id. A unitary result forms a complete, united whole. [d. 
117. Id. at 79. 
118. Diamond v. Chakrabarty, 447 U.S. 303 (1980). Ananda Chakrabarty filed a patent application in 
1972 which described a process to create a new genetically engineered strain of Pseudomonas 
aeruginosa capable of degrading liquid hydrocarbons. The application was assigned to the General 
Electric Company. The strain was unique because it could stably maintain four different plasmids not 
naturally found therein. Id. Acting in harmony, these plasmids degrade four different crude oil 
components and, as a result, can be effective in combatting oil spills and providing nutrients for aquatic 
life. 
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of a living microorganism created in a laboratory through genetic engineering. 
Implicitly, the case also determined the extent to which the Court would recog-
nize the patent system as a means of promoting technical innovation. 
In Chakrabarty, a patent examiner had rejected the patent claim for the mi-
croorganisms on the ground that living things are not patentable subject matter 
under Section 101.119 The Supreme Court disagreed. The Court ruled that 
Congress must define the limits of patentability, and that courts should therefore 
give patent laws a wide scope.120 The Court had previously cautioned other 
courts not to read into patent laws limitations which the legislature had not 
expressed.121 In its interpretation of the statute, the Court found that the statute 
did not necessarily preclude living things from patentability.122 With respect to 
the alleged hazards of recombinant DNA research,123 the Supreme Court recog-
119. In re Chakrabarty, 571 F.2d 40 (C.C.P.A. 1978). The patent examiner approved the claim for a 
method of production and innoculation of the microorganisms, but rejected the claims for the genet-
icaUy created bacteria strains. Chakrabarty appealed to the Patent Office Board of Appeals, which 
affirmed the initial decision, holding that the new bacteria were statutorily unpatentable material, 
rather than unpatentable as products of nature. The Court of Customs and Patent Appeals later 
reversed, relying on an earlier finding of patentability of living matter. In re Bergy, 503 F.2d 1031 
(C.C.P.A. 1977). 
120. Diamond v. Chakrabarty, 447 U.S. 303 (1980) (Brennan, White, Marshall and Powell, dissent-
ing). 
The history of the Chakrabarty case is noteworthy because of its complexity and impact. The Supreme 
Court had a petition for a writ of certiorari in a case which also involved issues of genetic engineering 
and patentability. Parker v. Bergy, 438 U.S. 902 (1978). The Court remanded Bergy to the Court of 
Customs and Patent Appeals for further consideration. The Patent Office therefore petitioned the 
Court of Customs and Patent Appeals to vacate its Chakrabarty decision. The Court of Customs and 
Patent Appeals then consolidated Chakrabarty and Bergy for reconsideration, and thereafter reaffirmed 
its earlier judgment that the claims were within statutory subject matter. Application of Bergy, 596 F .2d 
952,957 (C.C.P.A. 1979). The opinion was the lengthiest ever rendered by that court. The Supreme 
Court granted the government's petition for a writ of certiorari, but subsequently dismissed the case as 
moot when Bergy cancelled the disputed claim in his patent application. Parker v. Bergy, 444 U.S. 924 
(1980). This dismissal left only Chakrabarty for the Court's consideration. Diamond v. Chakrabarty, 444 
U.S. 1028 (1980). 
121. 447 U.S. at 308, citing United States v. Dublilier Condenser Corp., 289 U.S. 178, 199 (1933). 
122. 447 U.S. at 313. 
123. Some of the aUeged hazards include the escape of carcinogenic research microorganisms from 
the laboratory (rapidly reproductive in community water supplies) and the creation of genetically 
modified mammals. Golden, Shaping Life in the Lab, Tif1Ul, March 9, 1981, at 50-59. One observer notes, 
however, that the "extreme views heard at the height of the debate were groundless." Singer, Recombi-
nant DNA Revisited, 209 ScI. 1318 (1980). 
The development of the genetic engineering techniques ... was greeted, over the past 
decade, with both excitement and alarm. The possible benefits of the techniques were obvious, 
but some people felt there was reason for concern. Biologists called for an evaluation of the 
possible hazards of this research; the result was an unprecedented national and international 
effort in which the public governments and the scientific community joined to monitor 
research activities. New knowledge about the properties of genes and the behavior of the 
bacteria used in this work (usuaUy Escherichia coli) has led to a steady lessening of these concerns 
and to a relaxation of the guidelines that once restricted such experiments. In retrospect, with 
the advantage of hindsight, the concerns about hypothetical hazards seem ·to have been 
unwarranted. We know of no adverse effects from this research. The great potential of the 
new techniques, both in promoting the growth of basic knowledge and in making possible the 
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nized its lack of competency to rule upon these social policy issues,124 stating that 
Congress and the executive branch should more properly decide such issues.125 
By holding that the genetically engineered microorganisms in Chakrabarty were 
patentable, the Court implicitly signalled its intent to regard the patent system as 
a statutorily created means to promote scientific development. 126 Furthermore, 
the Court opened the door for the patentability of other biotechnological ad-
vances. 
The Supreme Court's expansive view of the patent system favors the potential 
patentability of a synthesized virus under a composition of matter analysis. 
Although scientists do not agree as to whether or not a virus is a living entity,127 
synthesis of products of direct benefit to society, is much closer to realization than seemed 
likely only a few years ago. 
Gilbert & Villa-Komaroff, Useful Prouins from Recombinant Bacteria, SCI. AM., Apr., 1980, at 90. 
124. 447 U.S. at 317. The Court recognized the impropriety of judicial attempts to regulate the 
course of scientific research, and stated that resolution of such issues must rest with Congress. Even if 
recombinant DNA organisms are potentially dangerous, that danger would not warrant the denial of 
patent protection. The grant of a patent does not give the patentee the right to practice his invention. 
Rather, the patentee has the right to exclude others from practicing it without his permission. [d. 
Further the patentee must produce and market a patented invention in accordance with the law. Thus, 
the conferral of the patent right does not eliminate the need for compliance with safety legislation. 
Cooper, supra note 33, at 34. 
125. 447 U.S. at 317. The Court invited Congress to review its decision. [d. Congress has considered 
various bills on this subject, but has yet to enact any statute that would affect recombinant research. A 
number of local municipalities and states, however, have enacted legislation controlling the kinds and 
scope of experiments that can be conducted. E.g., Cambridge, Mass. Code art. II § 11.7 (1977); 
Borough of Princeton, N.J., Code Ch. 26A, § 1 (1978); Amherst, Mass., By-Laws art. III, § 10 (1978); 
Berkeley, Cal., Ordinances No. 5010-N.W. (1977); see also N.Y. PuB. HEALTH LAw § 3220 (McKinney 
1978), MD. PuB. HEALTH CODE ANN. § 898 (1977). 
The National Institutes of Health (NIH) has achieved the most pervasive control of DNA experimen-
tation in its promulgation of the NIH Guidelines for Recombinant DNA Research (Guidelines or 
Rules), 45 Fed. Reg. 6724 (1980), amended at 45 Fed. Reg. 25367 (1980) and at 45 Fed. Reg. 50524 
(1980). Traditionally the NIH functions as a research-oriented government agency. Since promulgation 
of the NIH Guidelines, however, the NIH apparently has begun to assume a more regulatory function 
in the control of DNA experimentation, although interestingly enough, it has no staff to monitor 
compliance. 
Many experts agree that a strong federal presence in regulating recombinant DNA research is 
desirable. However, other observers argue that the guidelines should be voluntary because little 
evidence exists that there are hazards involved in such research. Dr. Paul Berg of Stanford University, 
for example, one of the three signatories of the letter which originally suggested a moratorium on 
recombinant DNA research, wrote that he believed the guidelines "are now dispensable." Dickson, DNA 
Panel Has Second Thoughts, 295 ScI. 447 (1982). See also Berg, Dissections and Reconstructions of Genes and 
Chromosomes, 213 ScI. 296 (1981). 
126. By assuring patent protection, the patent scheme stimulates research for further development 
of useful technologies, such as genetically-engineered microorganisms .. By promoting use of the patent 
system, the statute assures the public disclosure of the results of the research. The disclosure of such 
research should not only allay fears regarding genetic engineering, but also allow the public and 
Congress to identify those areas where prohibitions may be advisable. F. Fowler, Paunting Microor-
ganisms, 30 DRAKE L. REv. 635, 647-49 (1980-81). 
127. Common attributes of a living organism include: cellular organization; ability to derive energy 
from sources in the environment; motility; responsiveness to change in environmental conditions; and 
capacity to replicate. S. LURIA & J. BARNELL, JR., GENERAL VIROLOGY, 3 (1969) [hereinafter cited as 
LURIA & BARNELL]. 
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this factor is not determinative in establishing patentability, as indicated by the 
Supreme Court in Chakrabarty. 128 Instead, it is compliance with statutory criteria 
that determines patentability.129 
Viruses are chemically definable entities, whether existing inanimate in a test 
tube or functioning within a living cell.130 The capability of viruses to be either 
animate or inanimate is not the critical point, however. Instead, the focus in on 
the constituent elements of a synthesized virus which combine to form a "com-
position of matter." This synthesis of previously unrelated elements meets the 
requirements of patentability as composition of matter. 
2. The Synthesized Virus as a Process 
The analysis of the virus as a process under Section 101 is more complex than 
the composition of matter analysis. Patents for compositions of matter are 
distinct from patents for the process resulting in the production of matter.13l 
Patents for the former, if properly described, may exist independent of patents 
for the latter.132 Due to the constraints of language, the process of making a 
product sometimes defines the product. These products are "products-by-
process."133 The process, not the product, therefore, is the defined invention.134 
A process is an act or series of acts which transforms and reduces the subject 
matter to a different state or thing.13s A process patent is therefore one which 
treats certain materials to produce a certain result. 136 Although any set of steps 
may properly be labeled a process, Section 101 limits the granting of patents to 
invent:ed processes.137 
128. 447 U.S. at 313. 
129. [d. Once shown to be within the ambit of the statutory requirements, patentability is established. 
[d. at 310. 
130. PELcZAR, supra note 19 at 17. 
131. Holland Furniture Co. v. Perkins Glue Co., 277 U.S. 245, 254 (1928). A process consists of an 
act, operation, or step (or series of steps) performed upon specified subject matter to produce a physical 
result. Under the Patents Act, any combination of physical or manipulative steps may comprise a 
process. ROSENBERG, supra note 50, at 73-74. 
132. ROSENBERG, supra note 50, at 73-74. 
133. General Foods Corp. v. Carnation Co., 411 F.2d 528, 530 (7th Cir. 1969), eer!. denied 396 U.S. 
440 (1969). 
134. [d. 
135. ROSENBERG,supra note 50, at 78. See also Holland Furniture Co. v. Perkins Glue Co., 277 U.S. at 
254. 
136. Phillips Petroleum Co. v. Sid Richardson Carbon and Gasoline Co., 416 F.2d 10, 11 (5th Cir. 
1969). The court reaffirmed the doctrine of equivalence, whereby the patentee is protected from 
another's adoption of a process "that operates in substantially the same manner and under the same 
physical laws to produce the same result as that of the patented process." [d. See also Kemart Corp. v. 
Printing Arts Research Laboratories, Inc., 201 F.2d 624, 629 (9th Cir. 1953). 
137. In re Sarkar, 588 F.2d 1330, 1333 (C.C.P.A. 1978). The court denied a patent claim for a 
process of constructing a mathematical model of a waterway, holding that sets of steps conducted 
entirely by nature are not subject to patenting. [d. In essence, an "invented" process must be one which 
is the result of some degree of human intervention. A process which is entirely a function of natural 
steps is not patentable. [d. See also Chakrabarty, 447 U.S. at 309. 
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Most of the recent litigation concerning the patentability of processes involves 
computer and mathematical patent claims.13B Opponents of such applications 
stress that products of nature, such as algorithms,l39 are excluded statutorily 
from patentability.140 Opponents of the synthesized virus claim could analogize a 
synthesized virus to an inert receptacle, or mere description, of genetic informa-
tion, which is unpatentable. l4l The courts' determination of statutory subject 
matter focuses on whether a mathematical algorithm, formula or method of 
calculation is the basis for a process claim.142 
None of these is the basis for the synthesized virus claim. The synthesized virus 
is a product of the series of steps known as genetic engineering or recombinant 
DNA - an "invented process" pursuant to Section 101. Genetic engineering 
involves the alteration of an organism's genetic code.143 Because this process may 
138. See, e.g., Parker v. Flook, 437 U.S. 584 (1978). In Flook, the Supreme Court held a mathematical 
formula unpatentable, stating that the process itself, not merely the mathematical algorithm under 
consideration, must be new and useful. The Court considered novelty unimportant in the decision to 
grant a patent. See also Diamond v. Diehl', 450 U.S. 175 (1980) (relating to a mathematical calculation for 
transforming raw, uncured synthetic rubber into a different state); Matter of Application of Bradley, 
600 F.2d 807 (C.C.P.A. 1979) (patent denied for "Switch System Base Mechanism," relating to altering 
information in the computer's system base); Application of Maucorps, 609 F.2d 481 (C.C.P.A. 1979) 
(patent denied for computer-implemented model of sales organization); Application of Walter, 618 
F.2d 758 (C.C.P.A. 1980) (patent denied for algorithm relating to seismic prospecting and surveying); 
and Arshal v. United States, 621 F.2d 421 (Ct. Cl. 1980) (pertaining to a directional computer for 
aircraft flight control and directed toward a vectorial data processing system for extracting or prescrib-
ing directions and the rates of change from given input vectors). 
139. An algorithm is a mathematical formula or computational method. The Supreme Court's 
definition of an algorithm is "[al procedure for solving a given type of mathematical problem." 
Gottschalk v. Benson, 409 U.S. 63, 65 (1972). 
140. Flook, 437 U.S. at 593. See also Gottschalk v. Benson, 409 t.:.S. 63 (1972). 
141. The Court stated in Flook that a formula which merely describes a natural phenomena is 
unpatentable. Hence, the relationship described by E-mc' is not patentable. Nonetheless, an inventive 
application of this formula may be patented. Flook, 437 U.S. at 594. Analogizing this approach to that of 
a synthesized virus, opponents of patentability would argue that such a virus is nothing more than a 
genetic formula. However, the information represented by the virus' ,genetic code of recombinant DNA 
is far more than a mere mathematical representation. The unique arrangement of the genetic structure 
is unlike any other naturally-occurring virus, and was created by an inventive concept. On the other 
hand, a description of a regular virus contains nothing patentable; it is completely analogous to a 
formula of a natural phenomenon. 
142. See In re Diehr v. Lutten, 203 U.S.P.Q. 44 (1979). The case involved the subject matter 
patentability of a computer program process. The Court of Customs and Patent Appeals allowed the 
claim, stating: 
The Court's holding in Flook was "very simply" stated: "[Olut holding today is that a claim 
for an improved method of calculation, even when tied to a specific end use, is unpatentable 
subject matter under § 101." [d. n. 18. As in Benson, this holding has nothing to do with 
computers or computer programs per se. 
This, as we perceive it, is the direction which has been given u:; by the Supreme Court. Until 
the Court directs us otherwise, we continue to disagree with the notion that a claim may be 
rejected as nonstatutory merely because it involves a computer program or is computer-re-
lated. As far as we are concerned, claims may be rejected under § 101 because they attempt to 
embrace only a mathematical formula, mathematical algorithm, or method of calculation but 
not merely because they define inventions having something to do with a computer. 
/d. at 50. See also note 138 supra. 
143. See notes 1-4 and accompanying text supra. 
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occur at random in nature,144 e.g., by radiation, some opponents of the Chak-
rabarty claim 145 regarded this alteration aspect to be fatal to patentability.146 
However, when a scientist synthesizes a virus through the genetic engineering 
process, the resulting organism should be patentable for at least two reasons. 
First, "a claim does not recite a nonstatutory subject matter merely because an 
element or a step, when considered out of the context of the rest of the claim, is 
found to contain a[n unpatentable] natural law or mathematical formula."147 
The natural law premise that an organism is unique due to its genetic structure 
underlies the genetic engineering process,148 and thus, the synthesized virus 
embodies its recombined DNA structure. Nonetheless, simply because this 
natural law forms a step in the process of genetic engineering does not render 
the process unpatentable.149 Second, although the basic biotechnological meth-
ods involved in genetic engineering are not unique/50 their application to a virus 
is unique151 and, therefore, warrants patentability as a process. As of yet, synthe-
sis of a virus with which to "infect" a bacterium is one aspect of biotechnology 
with which patent law has not yet dealt, and thus is innovative. 
3. Novelty 
In addition to the requirement that a patent application satisfy the composi-
tion of matter or process analyses under Section 101, Section 102 imposes a 
requirement of novelty.152 This requirement should present little problem for 
144. Cohen and Shapiro, Transposable Genetic Elements, SCI. AM., Feb., 1980, at 40-41. The major 
discovery in the biological sciences during this century has been the essential nature of DNA as the 
genetic blueprint of life. PELCZAR, supra note 19 at 218. 
145. Respondent's Brief, Diamond v. Chakrabarty, 447 V.S. 303 (1980). 
146. [d. 
147. In re Johnson, 589 F.2d 1070, 1077 (C.C.P.A. 1978). In examining a claim involving methods 
for removing undesirable signal noises from seismic data, the court held that the claim was not rendered 
nonstatutory by the fact that the process at issue was implemented by a nonstatutory computer system. 
[d. 
148. EBERT, supra note 19 at 12. 
149. In re Sarkar, 588 F.2d 1330, 1333 (C.C.P.A. 1978). If the genetic engineering process were 
entirely composed of steps performed in nature, it would not be subject to patenting. 
[d. 
"Sets of steps conducted entirely by nature are not subject to patenting; they are not invented 
by man. Sets of steps occurring only in the mind have not been made subject to patenting 
because mental processes are but disembodied thoughts, whereas inventions which Congress is 
constitutionaUy empowered to make patentable are tangible embodiments of ideas the useful 
or technological arts." 
150. See Chakrabarty, 447 V.S. at 309. 
151. See text accompanying note 19 supra. 
152. 35 V.S.C. § 102 (1970). 
§ 102. Conditions for patentability; novelty and loss of right to patent. 
A person shaU be entitled to a patent unless -
(a) the invention was known or used by others in this country, or patented or described in a 
printed publication in this or a foreign country, before the invention thereof by the applicant 
for patent, or 
(b) the invention was patented or described in a printed publication in this or a foreign 
country or in public use or on sale in this country, more than one year prior to the date of the 
application for patent in the Vnited States, or 
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the virus patent application. The patentee only needs to establish that others 
have not known of, used or patented the synthesized virus in the United States or 
in a foreign country prior to submission of a patent application.153 
The requirement of novelty extends to foreign applicants. When a corre-
sponding foreign application154 is filed more than twelve months before the 
filing of the application in the United States, Section 102(d) bars the granting of 
a United States patent if the foreign country patented the invention before the 
U.S. filing date. 155 The filing of an invention in Great Britain, for Section l02(d) 
purposes, is the date the British patent is granted. 156 
Since a virus is a receptacle (or description) of information, some observers 
analogize the virus to other inventions which are unpatentable, such as mathe-
matical formulae or algorithms. 157 If such discoveries of natural, informational 
and inert phenomena were patentable, this would preclude their use by oth-
ers.158 Furthermore, an algorithm merely reveals a relationship that has always 
existed. 159 Recognition of such an existing principle carries with it no rights to 
Id. 
(c) he has abandoned the invention, or 
(d) the invention was first patented or caused to be patented, or was the subject of an 
inventor certificate, by the applicant or his legal representative or assigns in a foreign country 
prior to the date of the application for patent in this country on an application for patent or 
inventor's certificate filed more than twelve months before the filing of the application in the 
United States, or 
(e) the invention was described in a patent granted on an application for patent by another 
filed in the United States before the invention thereof by the applicant for patent, or on an 
international application by another who has fulfilled the requirements of paragraphs (1), (2), 
and (4) of section 371(c) of this title before the invention thereof by the applicant for patent or 
(f) he did not himself invent the subject matter sought to be patented, or . 
(g) before the applicant's invention thereof the invention was made in this country by 
another who had not abandoned, suppressed, or concealed it. In determining priority of 
invention there shall be considered not only the respective dates of conception and reduction 
to practice of the invention, but also the reasonable diligence of one who was first to conceive 
and last to reduce to practice, from a time prior to conception by the other. 
153. 35 U.S.C. § 102(a) (1970). Two commentators claim that the Patent Office standard for 
patentability has been reduced virtually to mere novelty; that old technology is repatentable via cosmetic 
change. Irons & Sears, Patent Reexamination: A Case of Administrative A7"Togation, 1980 UTAH L. REv. 287, 
289 (1980). Such an assertion is somewhat overstated. Recent decisions reveal the failure to reduce 
standards of patentability. See, e.g., note 138 supra. Further, the standard of review in these decisions is 
that the existence of similar technology in the prior art precludes the granting of a claim. 
154. In re Monks, 588 F.2d 308 (C. C.P.A. 1978). The case raised the issue of when an invention is 
deemed patented in Great Britain under 35 U.S.C. § 102(d). !d. 
155. Id. at 309. 
156. Id. The United States bars a patent if a foreign country patented, i.e., granted or issued, the 
invention before the U.S. filing date. Id. at 310. 
157. Weiss, United States: Summary of Court of Customs and Appeals In Re Bergy and In Re Chakrabarty, 18 
I.L.M. 983, 985 (1979) [hereinafter cited as Weiss]. 
158. Examples of other unpatentable mathematical formulae include the speed of light and the force 
of gravity. Both formulae represent natural phenomena, are informational and are inert. Yet the 
applicable patent statute may utilize either formulae in a unique, inventive manner. Thus, the formulae 
are patentable. See generally Parker v. Flook, 437 U.S. at 593. 
159. A natural phenomenon is never patentable. Id. 
1983] BIOTECHNOLOGY PATENT LAw DEVELOPMENTS 587 
exclude others from its enjoyment. Patentable subject matter, on the other hand, 
must be novel, not merely previously unknown.16o 
The inert nature of a mathematical formula is not fatal to a patent applica-
tion.161 Even though a phenomenon of nature may be well-known, an inventive 
application of the principle is patentable.162 Conversely, the discovery of such a 
phenomenon cannot support a patent unless there is some other inventive 
concept in its application.163 
In terms of patentability analysis, a virus created in a biotechnology laboratory 
is closer to a genetically engineered microorganism than a mathematical for-
mula.164 Scientists have artifically introduced, through genetic engineering tech-
niques, a plasmid which is habitually present in one species of microorganism 
into another species of microorganism, which does not normally carry out the 
same physiological activity.165 The recipient microorganism becomes endowed 
with that new property, thereby potentially becoming more useful than the 
previously existing strain.166 This procedure requires the scientist to identify 
microorganisms displaying a desired characteristic, isolate the plasmid contain-
ing the gene responsible for the characteristic, introduce the plasmid into the 
recipient microorganism and achieve compatibility and acceptability for the 
plasmid within the new microorganism.167 
Each of the procedural steps which have been applied to microorganisms 
involves the successful execution of highly sophisticated laboratory techniques in 
order tQ achieve a virus exhibiting a desired characteristic not found in na-
ture. 16S The successful completion of the process produces a virus which would 
160. ROSENBERG, supra note 50, at 13-14. Novelty is a requisite for patentability in both Great Britain 
and the United States. Patents Act, 1977, ch. 37 § 2; 35 U.S.C. § 102 (1970). 
161. Flook, 437 U.S. at 594. The only novel feature on a method for which a patentee filed an 
application was a mathematical formula. On certiorari the Supreme Court held the formula unpatent-
able. The identification of a limited category of useful, though conventional, post-solution applications 
of the formula did not make the patent eligible for patent protection. A process is not unpatentable 
under 35 U.S.C. § 101 simply because it contains a law of nature or mathematical algorithm. However, 
the process itself, not merely the mathematics algorithm, must be new and useful. The novelty of the 
algorithm and its applications are not determining factors in the award of a patent. [d. at 588-90. 
Congress resolved the Flook issue by enacting the Computer Software Copyright Act of 1980. 
Computer programs are included among writings to which the inventor may obtain exclusive rights. 
The effect of such protection will be the stimulation of investment in development of new programs and 
new software technology. Holden, Briefing, 211 ScI. 37 (1981). 
162. See, e.g., notes 137 8< 159 supra. 
163. Flook, 437 U.S. at 594. 
164. A synthesized virus is a genetically engineered product, containing unique genetic information, 
with consequent unique application. See note 19 and accompanying text supra. A mathematical formula, 
representing a natural phenomenon, does not contain unique information, regardless of its application. 
Flook, 437 U.S. at 594. See generaUy note 161 and accompanying text supra. 
165. Amicus curiae brief of American Society for Microbiology, Parker v. Chakrabarty, 447 U.S. 303 
(1980). 
166. See notes 2-8 and accompanying text supra. 
167. See notes 1, 3, 4 8< 8 supra. 
168. [d. 
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be "new" within the statutory construction of Section 102. Unlike the "inert" 
algorithm, the new virus is a novel subject matter, and thus, the analysis underly-
ing non-patentability of the algorithm is inapplicable to the virus. The virus 
claim, therefore, appears to meet the requirements of Section 102. 
4. Nonobviousness 
Section 103 of the Patents Act169 is often the most difficult requirement of 
patentability to apply.170 It requires that the claimed subject matter be nonobvi-
ous, at the time the invention was made, to a person having ordinary skill in the 
art to which the claimed subject matter pertains. l71 Section 103 frequently 
requires that the Patent Office make a complex factual analysis of the claims of 
the patent in light of the technology that existed at the time of the invention.172 
Case law indicates that a synthesized virus claim would meet the Section 103 
requirement of nonobviousness. U.S. courts have held that an invention is not 
patentable if a person of ordinary skill in the art could have created the inven-
tion.173 The test is not whether the object is an improvement in the art or 
whether the object works better,174 because an improvement in the art is not 
entitled to patent protection.175 If the claim covers an invention that combines 
old and well-known elements, as does a synthesized virus claim,176 one of the 
factors a court will look for in analyzing Section 103 nonobviousness is syner-
gism, i.e., that which results "in an effect greater than the sum of the several 
effects taken separately."177 Courts also look, in considering patentability from a 
Id. 
169. 35 U.S.C. § 103. 
§ 103. Conditions for patentability; non-obvious subject matter. 
A patent may not be obtained though the invention is not identically disclosed or described 
and set forth in section 102 ofthis title, if the differences between the subject matter sought to 
be patented and the prior art are such that the suJ!iect matter as a whole would have been 
obvious at the time the invention was made to a person having ordinary skill in the art to which 
said subject matter pertains. Patentability shall not be negatived by the manner in which the 
invention was made. 
170. See Charney, Palenl Infringement and Validity: A Guide for the General Practitioner, 55 CALIF. STATE 
B.]. 202, 204 (1980). 
171. 35 U.S.C. § 103 (1970). See Gershman and Scafetta,Patents £In Microorganisms, 21 IDEAI].L. & 
TECHNOWGY 1 [hereinafter cited· as Gershman and ScafettaJ for strategic considerations when filing a 
patent claim for genetically engineered products. 
172. See, e.g., cases cited in note 138 supra. 
173. See, e.g., Airlite Plastics Co. v. Plastilite Corp., 526 F.2d 1078, 1082 (5th Cir. 1975), cm. denied, 
425 U.S. 936 (1976). 
174. Id. 
175. Reinke Mfg. Co. Inc. v. Sidney Mfg. Corp., 594 F.2d 644 (8th Cir. 1978). The case dealt with 
slight modifications in stress design relating to an electrically driven circular irrigation system. Id. at 645. 
The court also found that the claim could not overcome the requisite nonobviousness when analyzed in 
terms of whether a hypothetical person skilled in the relevant art could have accomplished the same 
result.Id. at 648-52. See also Sakraida v. Ag Pro Inc., 425 U.S. 273, 281 (1976); Great A&P Tea Co. v. 
Supermarket Equip. Corp., 340 U.S. 147, 152-53 (1950). 
176. See note 161 and accompanying text supra. 
177. Anderson's Black Rock, Inc. v. Pavement Salvage Co., 396 U.S. 57,61 (1969). 
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nonobviousness analysis, for the possibility that the invention may solve a prob-
lem in a way not previously recognizedYs 
The synthesized virus, having a unique genetic structure, is useful in new areas 
of research. 179 Because such a virus consists of a genetic reconstruction, the 
Patent Office may require a showing of synergistic qualities. In that case, the 
claimant need only demonstrate that no other single virus or group of viruses is 
genetically capable of performing like the synthesized virus. ISO The claimant 
may do this by demonstrating that the synthesized virus solves a previously 
recognized problem of disease research. lSI The virus is capable of solving such a 
problem because the utility of a synthesized virus lies in its uniquely predictable 
nature. IS2 It is this need for non-random variables in virology research that is the 
basis for the patentability of a synthesized virus. 
IV. CONCLUSION 
In contrast to the United States, Great Britian's patent system required nearly 
complete revision in order to handle the recent explosion in technical innova-
tion. Whereas the Supreme Court was able to analyze emergent technology, such 
as genetic engineering, within the framework of existing patent law, British courts 
frequently found that that nation's patent system was insular and outdated. 
During the last decade, lawmaking entities in both Great Britain and the 
United States were aware of developments in patent law beyond the arenas of 
Parliament and the Supreme Court. Great Britain's participation in European 
patent conventions afforded the nation access to a flexible and transnational 
patent scheme, one which Great Britain selectively incorporated into its Patents 
Act 1977. In ruling on the patentability of a genetically engineered microor-
ganism, the Supreme Court in Chakrabarty was at the focus of a multitude of 
divergent sources of opinion. Some factions believe that life forms should not be 
patentable. They feel that such research should be halted, or at least not given 
178. Solder Removal Co. v. U.S. International Commission, 582 F.2d 628, 635 (C.C.P.A. 1978). The 
court held the patent claim invalid because one skilled in the art, and having the prior art of record 
before him, would have found it obvious to utilize the procedure claimed in the patent application.ld. at 
638. 
In In re Goodwin, 576 F.2d 375, 377 (C.C.P.A. 1978), the court refused to recognize "obvious to try" 
rejections and noted that "obvious to try" is not the standard of 35 U.S.C. § 103 (1970). See also cases 
cited in notes 173 & I 75 supra. 
179. Mechanical purification and isolation has greatly advanced virology research, but, as in any 
other type of biochemical work, perhaps the single most important research aid is a reasonably 
convenient means for the bioassay of fractions. LURIA & BARNELL, supra note 127, at 3. See also notes 1-3 
and accompanying text supra. 
180. A group of viruses, representing the constituent genetic elements of the synthesized virus, may 
be similar to the claimant's genetically engineered virus, but synergistically the synthesized virus results 
"in an effect greater than the sum of the several effects taken separately." Anderson's Black Rock Inc., 396 
U.S. at 61. 
181. See notes 1-7 and accompanying text supra. 
182. See notes 1-7 & 88 and accompanying text supra. 
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impetus in the form of patent protection. Consequently, the patent system in the 
United States was also subject to reevaluation. The Court in essence determined 
that the patent system in the United States should continue to promote research 
and development. 
The contemporaneous developments of patent law in Great Britain and the 
United States are less a result of coincidence and more a response to the rapid 
advances in innovation. One such advance which is at the leading edge of 
science, technology and public policy is biotechnology. In an attempt to meet 
successfully the rapid growth in science and technology, Great Britain enacted 
the Patents Act 1977. A new invention, which involves an inventive step and is 
capable of industrial application, qualifies for patent protection. The Patents Act 
1977 incorporates broad language in order to assure maximal protection for 
innovators. The motivation underlying the Act is to encourage research and 
development of technologies beneficial to society. A biotechnologist who success-
fully synthesizes a virus, which provides a welcome degree of certainty in disease 
research, will receive patent protection. More importantly, society will benefit 
since patent protection will encourage further worthwhile research which might 
otherwise have been hampered, postponed or thwarted altogether. 
In the United States, the Supreme Court in Chakrabarty recently gave an 
expansive interpretation to the Patent Act of 19.52 and thereby further 
broadened the opportunity of patent protection for emergent technology. 
Whether examined via composition of matter or process claim, the hypothetical 
synthesized virus claim is patentable subject matter under the Patent Act of 1952. 
The claim also passes the tests of novelty and nonobviousness. As such, the claim 
is entitled to U.S. patent protection. 183 
In sum, the current patent systems in Great Britain and the United States 
provide the necessary incentive for the disclosure of patentable emergent 
technologies. This interface of science, technology and public policy results in 
society'S net benefit of encouraging further worthwhile research which might 
otherwise have remained uninspired. 
Bradford C. Auerbach 
183. Gershman and Scafetta, supra note 171. at 4. 
